electroCore, Inc. Common Stock (ECOR) is a publicly traded Healthcare sector company. As of May 21, 2026, ECOR trades at $6.13 with a market cap of $48.61M and a P/E ratio of -3.44. ECOR moved +2.29% today. Year to date, ECOR is +29.60%; over the trailing twelve months it is +15.44%. Its 52-week range spans $4.16 to $19.49. Analyst consensus is strong buy with an average price target of $16.62. Rallies surfaces ECOR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Quell Plus Physical Therapy Reduces Fibromyalgia Pain by 1.2 Points in 384-Patient Trial: electroCore published a 384-patient cluster randomized trial evaluating Quell plus outpatient physical therapy in fibromyalgia, enrolling 191 in PT-Quell and 193 in PT-only groups. At day 60, PT-Quell reduced movement-evoked pain by 1.2 points versus PT alone, sustained six months, with 81% reporting daily use.
| Metric | Value |
|---|---|
| Price | $6.13 |
| Market Cap | $48.61M |
| P/E Ratio | -3.44 |
| EPS | $-1.77 |
| Dividend Yield | 0.00% |
| 52-Week High | $19.49 |
| 52-Week Low | $4.16 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $34.90M |
| Net Income | $-15.38M |
| Gross Margin | 87.25% |
3 analysts cover ECOR: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $16.62.